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The MYC gene is induced by a wealth of growth factors and is essential for most normal cells to proliferate 1, 2 . Following the deregulation of MYC expression by translocation, gene amplification or aberrant signalling, MYC becomes a potent oncoprotein that promotes unrestrained cell proliferation 3 . Approximately 70% of human tumours have elevated MYC expression 4 , and suppression of MYC expression can lead to the regression of tumours 5 . Therapeutic interference of MYC oncogenic activity could offer an important advance in cancer treatment 6 . This central role for MYC in the growth of both normal and cancer cells sustains a broad interest in MYC function. The MYC protein is a sequence-specific DNAbinding protein that functions as a transcription factor, and this role has focused MYC research on two key questions: how does MYC function biochemically to regulate transcription and what are the MYC-responsive target genes that control cell proliferation and cell transformation? Progress has been made in answering these questions (reviewed in . Over the past few years, however, experimental findings have raised the intriguing possibility of transcription-independent functions of MYC.
Here, we discuss the finding that MYC regulates protein expression by a novel mechanism -that is, by regulating mRNA translation 10 . This mechanism can occur independently of MYC-induced transcription and is therefore a novel MYC function that is likely to have an integral role in mediating MYC-dependent functions. We also discuss a second transcription-independent function for MYC -the direct regulation of DNA replication by MYC-dependent recruitment of pre-replicative complex components 11 .
MYC as a transcription factor MYC dimerizes with the basic helixloop-helix (bHLH)/Leu-zipper protein MYC-associated factor-X (MAX) through a C-terminal HLH/Leu-zipper domain to facilitate DNA binding 12 . The N terminus of MYC proteins contains a transactivation domain and a number of conserved motifs known as MYC boxes (fIG. 1) . MYC boxes are well conserved across species. In particular, MYC box II (MBII) is highly conserved and is the most important region of the transactivation domain. MBII is necessary for MYC binding to most cofactors, for the transactivation and repression of most MYC target genes and for the efficient execution of the biological effects of MYC 9 . Global analyses have been performed in a comprehensive range of cellular systems and showed that MYC is a weak but expansive transcription factor that upregulates or represses the transcription of ~10% of the genome. The expression of each gene is typically regulated by less than twofold 4, 7, 9 . MYC also increases the transcription of the genes that are regulated by RNA polymerase (pol) I and RNA pol III , and regulates transcription of microRNAs 18, 19 . Although microRNA expression might have an impact on mRNA translation, this effect is an indirect consequence of MYC-dependent transcriptional mechanisms. Abstract | MYC is a potent oncogene that drives unrestrained cell growth and proliferation. Shortly after its discovery as an oncogene, the MYC protein was recognized as a sequence-specific transcription factor. Since that time, MYC oncogene research has focused on the mechanism of MYC-induced transcription and on the identification of MYC transcriptional target genes. Recently, MYC was shown to control protein expression through mRNA translation and to directly regulate DNA replication, thus initiating exciting new areas of oncogene research. The prevailing model of MYC-mediated transcription postulates that MYC increases local histone acetylation at promoters 7, 9 (fIG. 2a). MYC binds to histone acetyltransferase complexes including TRRAP (transformation/transcription-domain-associated protein) and either general control of amino-acid-synthesis protein-5 (GCN5) or TIP60, which preferentially acetylate histones H3 or H4, respectively [20] [21] [22] . MYC also binds to the p300/CBP (CReB-binding protein) acetyltransferases 23 . Recruitment of TRRAP and associated acetylation activity is also associated with the stimulation of RNA pol I and pol III transcription 14, 15, 17 . The histone acetylation that results then opens the chromatin and provides docking sites for acetyl-histone-binding proteins, including GCN5 and the SWI/SNF chromatinremodelling complex, both of which correlate with increased transcription 24, 25 ( fIG. 2a) . Transcription-factor-mediated recruitment of histone acetyltransferases is now recognized to be a major mechanism of transactivation, and many other transcription factors, including TCF (T-cell factor), e2F, the tumour suppressor p53 and Gal4, have been subsequently found to use this mechanism 26 . Our understanding of the factors that regulate transcription has changed in light of a recent global genome analysis that reports the presence of paused RNA pol II at most cellular promoters 27 . This study expands on earlier work that showed paused RNA pol II at specific promoters, including those of heat shock and MYC genes 28 . This finding suggests that regulation of transcription also occurs at the level of transcriptional elong ation and not just at transcriptional initiation. RNA pol II undergoes a cycle of phosphorylation and dephosphorylation during transcription (BOX 1) and, with its C-terminal domain (CTD) in a hypophosphorylated form, RNA pol II is recruited to promoters. Phosphorylation of the CTD occurs during transcription initiation and elongation, whereas the CTD must be dephosphory lated to allow RNA pol II to be recycled for another round of transcription. RNA pol II has been found to pause on most promoters after transcribing approximately 20-40 bases. Specific signals and cofactors then stimulate transcriptional elongation and further RNA pol II phosphorylation 28, 29 . This model fits well with the earlier finding that MYC does not induce transcription of the target gene CAD (carbamoylphosphate synthetase-2, aspartate transcarbamylase, dihydroorotase) by driving RNA pol II recruitment, but rather stimulates the release of paused RNA pol II from the promoter and stimulates subsequent transcriptional elongation 30 (fIG. 2b ). This correlates with a MYC-dependent increase in RNA pol II phosphorylation at the CAD promoter, and the MYC transactivation domain was shown to bind CTD kinases 31 . MYC has also been found to recruit CTD kinases and basal transcription factors to a number of other promoters 32 . We recently expanded this finding by demonstrating that the MYC induction of RNA pol II phosphorylation occurs globally throughout the nucleus; it can be detected in the total cellular pool of RNA pol II rather than simply at MYC target-gene promoters 10 . This finding prompted us to question the definition of MYC as simply a traditional transcription factor and led us to investigate novel, transcription-independent roles of MYC.
Emerging novel functions of MYC
A number of experimental findings have suggested that MYC might have biologically significant, transcription-independent functions. First, MYC biological activity can be uncoupled from the regulation of transcription by mutant analysis. Mutations near the DNA-binding domain can reduce the DNA-binding activity of MYC with no effect on MYC-dependent cell proliferation and rat embryo fibroblast cell transformation 33 . Second, MYC mutants that cannot dimerize with MAX or lack DNA-binding activity can promote cell proliferation (albeit at half the rate that is induced by wild-type MYC) 10 . These findings imply that inherent DNA binding and transcriptional activation are not required for every biological activity of MYC. These observations are not completely novel. Although the neuronal PC12 cell line The MYC transactivation domain recruits acetyltransferase complexes that contain transformation/transcription-domain-associated protein (TRRAP) and either general control of amino-acid-synthesis protein-5 (GCN5) or TIP60, which preferentially acetylate histones H3 or H4, respectively. MYC can also recruit p300/CReBbinding protein (CBP). These complexes alter the acetylation of nucleosomes around MYC target genes, and these acetylation marks might also recruit other nuclear factors that influence transcription, such as the SWI/SNF chromatin-remodelling complex (not shown). b | MYC recruits basal transcription factors and promotes the clearance of promoters through RNA polymerase (pol) II. RNA pol II is frequently paused on promoters after phosphorylation of Ser5 on the RNA pol II C-terminal domain (CTD) and synthesis of a short (20-40 base) segment of mRNA 28 . The MYC protein can promote a paused RNA pol to continue transcription of the mRNA by recruiting the P-TeFb (positive transcription-elongation factor-b) complex, which phosphorylates the CTD on Ser2 and promotes transcriptional elongation.
does not express MAX, MYC was found to inhibit differentiation of PC12 cells 34, 35 . MAX is required for binding of MYC to DNA 36, 37 . However, these experiments did not address whether there was another dimerization partner or rare MYC homodimer that could account for this effect.
MYC drives mRNA cap methylation. How can the expression of MYC mutants that lack DNA-binding activity (such as expression of the transactivation domain alone) promote cell proliferation? We recently found that MYC can increase protein abundance by directly regulating the translation of individual mRNAs. The first hint towards this novel MYC mechanism came from the observation that the protein levels of several cyclin and cyclin-dependent kinases (CDKs), which are required for cell-cycle progression and transcription, abundantly increased in response to MYC expression without any change in their mRNA levels or in their requirement for the DNA-binding domain of MYC 10 . Conversely, reducing the level of MYC in normal fibroblasts by small interfering RNA led to a suppression of cyclin and CDK protein levels without causing a suppression of mRNA levels, demonstrating that endogenous MYC protein has an activity that is comparable to the MYC mutants that lack direct DNA-binding activity.
Although there were other possible explanations that could have accounted for this, such as increased protein stability, the mechanism by which MYC increases expression of cyclins and CDKs proved to be surprising. MYC was found to increase the translation of specific mRNAs by promoting the methylation of the 5′ mRNA guanine or 'cap' (Ref. 10) , which is an essential step for protein-coding gene expression 38, 39 . Genes that are subject to MYC-dependent cap methylation, for example, cyclin T1 and CDK9 (Ref. 10) , represent a novel set of MYCresponsive genes. As native levels of MYC regulate the expression of these proteins without changes in mRNA abundance, this transcription-independent activity has the potential to influence all aspects of MYC biology in both normal and tumour cells.
During the early stages of transcription mRNA is capped and methylated
. Cap methylation is necessary for the binding of translation factors to the mRNA and thus is required for translation [38] [39] [40] . As the nascent mRNA emerges from RNA pol II, capping enzyme (Ce) adds an inverted guanylyl group or 'cap' to the 5′ end. All mRNA that can be isolated from eukaryotic cells is probably capped (guanylylated) because uncapped mRNA is rapidly degraded 41 . However, mRNA cannot be translated efficiently unless the cap is subsequently methylated by an RNA methyl transferase (RNMT) 39
. Both Ce and RNMT are recruited to mRNA after transcription initiation by binding specifically to the RNA pol II CTD, which has been phosphorylated on Ser5 by the kinase TFIIH 38 . This phosphorylation occurs during the early stages of transcription, thus coordinating the recruitment of Ce and RNMT with the emergence of the mRNA 5′ end. The finding that MYC induces mRNA cap methylation reveals for the first time that these processes are not constitutive for every mRNA and that this can be an important regulatory mechanism for some genes 10 .
Previously, mRNA cap methylation was not widely recognized to be a regulated process because both biochemical and genetic studies have assessed the modification of the total mRNA pool 39 . However, the potential for differential regulation of mRNA capping and cap methylation was known to exist. Biochemical studies had shown that mRNA cap addition and cap methylation are distinct biochemical steps in mRNA processing 42 . Furthermore, yeast experiments have shown that the RNMT moves with RNA pol II further into the gene body than the guanylyltransferase 43, 44 , where it might have a role in transcription elongation that is independent of its methyltransferase activity 45 . RNA pol II Ser5 is phosphorylated predominantly by TFIIH, and MYC has been found to promote TFIIH recruitment and therefore promote subsequent RNA pol II phosphorylation 10, 32 . TFIIH recruitment and RNA pol II phosphorylation both correlate with increased mRNA cap methyl ation 10 . However, MYC can stimulate the methylation of specific mRNA, which prompts us to propose a model whereby methyltransferase recruitment requires a higher or qualitatively different level of RNA pol II phosphorylation than the guanylyltransferase. An unexpected finding was that TFIIH recruitment, RNA pol II phosphorylation and mRNA cap methyl ation on a subset of genes could be driven by the expression of the MYC transactivation domain alone -independently of the DNA-binding domain of MYC and of direct binding of MYC to DNA 10 
(fIG. 3).
Insight into this mechanism came from the finding that the transactivation domain could be recruited to chromatin-packaged Nature Reviews | Molecular Cell Biology Initial promoter recognition and pre-initiation-complex formation occurs with an unphosphorylated CTD. Following transcription initiation, the CTD is phosphorylated on Ser5 by the transcription factor TFIIH, after which the polymerase often pauses. Transcriptional elongation is stimulated by P-TEFb (positive transcription-elongation factor-b), which phosphorylates Ser2 of the CTD. The CTD is dephosphorylated during and after transcription termination to facilitate a new cycle of transcription. 5′-GpppN AAAAAA P P P P P P P P Pol II mRNA P P P P P P P P . We propose a model in which the MYC transactivation domain can be recruited to promoters by MYC cofactors, provided these cofactors have already been recruited by other transcription factors. If the MYC transactivation domain binds to cofactors that are recruited to promoters through some other DNAbinding protein, then MYC will colocalize to the same promoters. This model could explain earlier observations, which showed that MYC binds to a large fraction of promoters with no apparent requirement for a consensus binding site 46 . However, we found that MYC binding correlated with changes in RNA pol II CTD phosphorylation and cap methylation. This correlation implies that the MYC transactivation domain is not simply engaged in cofactor recruitment but might also modulate the activity of cofactors. This mechanism is similar to the mechanism proposed for the stimulation of RNA pol III transcription, in which MYC recruits TRRAP and promotes histone H3 acetylation, which in turn recruits TFIIIB and RNA pol III. However, in contrast to RNA pol II, RNA pol III stimulation involves increased RNA pol III recruitment to the promoter and requires both the N terminus and C terminus of MYC 13, 14 .
MYC controls DNA replication. Along with transcription, the most important nuclear function is DNA replication. The genome must be faithfully replicated each cell cycle and the chromosomes must be segregated to the daughter cells. Disruption of any step in this process, such as a stalled replication fork or DNA damage incurred during S phase, activates a checkpoint that halts the cell cycle until the lesion can be repaired 47 . Failure to correct this damage leads to a mutation and/or genomic instability.
Previous studies have provided a link between MYC and genomic instability 48, 49 , but it was postulated that this was an indirect consequence of transcriptional activity. A recent study describes a direct, non-transcriptional role for MYC in the initiation of DNA replication 11 . MYC was found to bind to numerous components of the prereplicative complex, including MCM proteins, ORC2, CDC6 and CDT1, and localize to early sites of DNA replication. These observations suggested that MYC might directly control the initiation of S phase and that the MYC effects on genomic instability might not depend on the transcriptional
Box 2 | Mechanism of mRNA cap methylation
The primary mRNA transcript contains a triphosphate at its 5′ end, 5′-ppp (step 1). Capping enzyme (CE) is recruited to the phosphorylated C-terminal domain (CTD) of RNA polymerase (pol) II during the early stages of transcription and adds an inverted guanine 'cap' at the 5′ end, thereby producing 5′-Gppp (step 2). CE is a bifunctional enzyme that has both triphosphatase and guanylyltransferase activities. The 5′-Gppp cap is then methylated on N7 by a second enzyme, the cap RNA methyltransferase (RNMT), to produce 5′-m7Gppp (step 3). 5′-Gppp-capped mRNAs are stable but are weakly translated. Methylation of this cap is required for eukaryotic translation initiation factor-4E (eIF4E) binding and recruitment onto ribosomes for translation. . 2 ). At other promoters (right), MYC stimulates mRNA cap methylation through TFIIH stimulation by the MYC transactivation domain and through the subsequent recruitment or activation of RNMT by C-terminal domain phosphorylation. In doing so, MYC functions as a transcription-independent factor. Activation of direct targets is MYC-associated factor-X (MAX)-dependent (left), whereas activation of transcription-independent targets is MAX-independent (right).
induction of S-phase-promoting genes. Taking advantage of Xenopus extracts (which support cell-cycle-regulated DNA replication in the absence of transcription and new protein synthesis), it was found that depletion of MYC decreased DNA synthesis and addition of recombinant MYC protein rescued DNA synthesis. This activity required intact MYC protein because neither the N terminus nor C terminus alone could rescue the defects observed. Levels of MYC protein seem to govern the number of active replication origins in both Xenopus and mammalian cells, suggesting that MYC functions to control origin selection. Aberrant firing of replication origins can be a source of replicative stress and can elicit a DNA-damage response. DNA damage stimulated the accumulation of H2A.X Ser139 phosphoryl ation, which was also stimulated by MYC induction. Phospho-H2A.X accumulation was dependent on MYC overexpression in S phase. This argues that the DNA-damage response was due to a defect in DNA replication.
These findings provide an unexpected link between MYC and a non-transcriptional process, DNA replication. Because this activity is dependent on the integrity of both the N-terminal and C-terminal domains of MYC, it suggests that MYC directly binds to DNA to recruit factors that govern the firing of replication origins. The selection of origins of replication in metazoan cells remains a puzzle 47 , but MYC was found to localize to a known origin of replication of the MYC gene itself 11 . If MYC is stimulating the firing of replication origins in normal cells, then continual overexpression of MYC in tumours could affect tumorigenesis by causing increased DNA damage. Continual accumulation of DNA damage from replicative stress and genomic instability could accelerate tumorigenesis in any tumour with abnormally high levels of MYC.
Conclusions and future perspectives
The sequence-specific transcription-factor field is built on the general assumption that all biological activity is dependent on conventional DNA-binding mechanisms, predominantly through cofactor recruitment to promoters. We consider the MYC oncogenic transcription factor in a new light: that the modular domains containing DNA-binding and transactivation activities might have independent functions with significant biological impact. The transactivation domain alone can stimulate both cell proliferation and global RNA pol II phosphorylation at physiological levels. By separating the functions of the transactivation and DNA-binding domains, a novel mechanism of gene regulation was revealed, namely the modulation of mRNA cap methyl ation. Changes in mRNA cap methyl ation can enhance or suppress protein expression in the absence of any changes in mRNA levels and hence alter gene expression through a transcription-independent mechanism. Beyond the transcriptional and transcription-independent functions of MYC in controlling gene expression, MYC might have an important role in setting the number of origins in DNA replication. The potent oncogenic activity of MYC might be dependent on both widespread activation and repression of target genes and on a transcription-independent capacity to regulate the translation and replication apparatus. These findings add to the complexity of understanding the function of MYC in cancer cells and might provide novel activities for therapeutic targets.
Abstract | Covalent post-translational modifications (PTMs) provide vast indexing potential and expanded protein use. The 'histone code' hypothesis has inspired rapid advances throughout chromatin biology, and has recently been tapped for its relevance to non-histone proteins. Comprehensive analyses suggest that rather than constituting a general code, the covalent modifications of proteins (including histones) provide surfaces that are recognized by effectors that can give rise to intricate interactions and downstream events. These are reminiscent of other regulatory cascades in transcription and cell signalling.
Biological complexity cannot simply be defined by the number of genes that an organism possesses. We have learned that more advanced species evolved additional regulatory features that allow for an increased number of functions and increased adaptability. Ample evidence suggests that these additional modes of functional indexing are not only diverse, but that they work together to accomplish a specific biological outcome.
In eukaryotic organisms, covalent posttranslational modifications (PTMs) on proteins result in many specific functions. Histone polypeptides, which are intimately associated with DNA to form chromatin, are subject to many PTMs. It has been speculated that histones provide an additional layer of indexing potential to the genome, primarily through epigenetic phenomena (heritable changes in genomic function that do not occur through alterations in the DNA sequence) 1, 2 . The 'histone code' hypothesis predicts that diverse covalent modifications within the highly accessible histone tails are read by effector molecules, which in turn mediate distinct outcomes. It has been suggested that these chromatin marks might function in a combinatorial manner, thereby increasing their indexing potential or capacity to store information. If these PTMs should distinguish themselves as components of a code, they could be indicative of specific biological outcomes, presuming that these patterns of marks are fully characterized at a molecular level. The 'epigenetic code' is an extension of this idea: it suggests that the downstream events that stem from code recog nition facilitate epigenetic processes 2 . Histone methylation has received special attention with respect to its indexing potential because it is available in three distinct forms (mono-, di-and trimethylated forms), and has slow turnover in vivo under normal cellular conditions [3] [4] [5] [6] [7] . This allows for the long-term propagation of information to progeny. More recently, a growing number of reports have shown that non-histone proteins are methylated 8, 9 (TABLe 1) . Some of these methylated targets are also subject to different types of PTMs, thereby drawing comparisons to histone tails. In some examples, single Lys residues within non-histone proteins can be targeted by varying types of PTMs that provide additional regulatory layers. As such, it has been speculated that the same principles that apply to a putative histone code can also apply to non-histone proteins 10, 11 . It is important to examine the evidence that supports the existence of a histone and/or protein code in consideration of the consequences that this framework would have for predicting downstream events.
The protein code concept
Protein phosphorylation is the most extensively studied PTM and has been shown to have important roles in most, if not all, cellular processes. In particular, phosphorylation has been well established to promote or inhibit protein-protein interactions. For example, the Src-homology-2 (SH2) domain selectively recognizes phosphorylated Tyr residues in signalling molecules and facilitates distinct cellular pathways in response to external cues 12 . under defined conditions, these phosphorylation events can be predictive of distinct biological events. For example, Tyr autophosphorylation of the platelet-derived growth factor (PDGF) receptor allows the docking of SH2-domain-containing phospholipase Cγ kinase to these modified Tyr residues, which in turn activates the inositol phospholipidsignalling pathway 13 . Therefore, from a restricted point of view, non-histone-protein phosphoryl ation abides by the basic principle of a code -that PTMs can be predictive of biological function.
By definition, a protein code suggests that PTMs (either single PTMs or PTMs in combination) are read by effector molecules
